FDA Approves Denali’s Avlayah for Hunter Syndrome
Get the Health newsletter
Daily health & science — research, biotech, public health, the studies worth knowing. Free.
- FDA approved Denali Therapeutics' new medicine Avlayah for Hunter syndrome on Wednesday.
- Avlayah is the name of Denali Therapeutics' newly approved treatment for Hunter syndrome.
- FDA has recently taken tougher stances on rare disease drugs, as reflected by the Avlayah approval and recent rejections.
- Regenxbio had its Hunter syndrome gene therapy rejected by the FDA last month, with the agency demanding more clinical data.
- Advocates expressed concern that the gene therapy denial highlighted the FDA’s heightened scrutiny of rare disease treatments, affecting expectations for Avlayah.
Why it matters: Patients with Hunter syndrome gain a newly approved therapy, while the FDA’s stricter rare‑disease review raises the bar for future developers, potentially delaying or denying other treatments, as seen with Regenxbio’s gene therapy rejection, and signaling heightened regulatory scrutiny that could affect the pipeline of rare‑disease drugs.
Ask SkimNews
